Madrigal Pharmaceuticals, Inc. (MDGL)
NMS · Healthcare · Biotechnology
$534.49
+0.26%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$12.35B
Shares Outstanding
23.1M
P/S (TTM)
9.6x
Exchange
NMS
Currency
USD
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 287.3M | 321.1M | 311.3M | 364.3M |
| Gross Profit | 269.1M | 296.6M | 284.5M | 324.2M |
| Operating Income | (114.0M) | (59.6M) | (92.7M) | (56.3M) |
| Net Income | (114.2M) | (58.6M) | (94.4M) | (57.9M) |
| Diluted EPS | $-5.08 | $-2.57 | $-3.25 | $-1.99 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 180.1M | 958.4M |
| Gross Profit | 0.00 | 0.00 | 173.9M | 902.3M |
| Operating Income | (293.6M) | (380.5M) | (497.9M) | (300.1M) |
| Net Income | (295.4M) | (373.6M) | (465.9M) | (288.3M) |
| Diluted EPS | $-17.23 | $-19.99 | $-21.90 | $-12.85 |